Johns HopkinsBaltimore, Maryland, United States
Disclosure(s): No financial relationships to disclose
312 - Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for Multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
Friday, October 18, 202410:54 AM – 11:06 AM US PT
314 - Ceftazidime-Avibactam Versus Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacterales Infections
Friday, October 18, 202411:18 AM – 11:30 AM US PT
